| Name | Title | Contact Details |
|---|
With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.
Better chemistry committed to the world`s biggest problems
Barc USA is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Decoding the dark matter of the human genome to uncover novel ways to treat disease Discover More
ChemDiv is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.